Extracellular Vesicle-Associated Neutrophil Elastase Activates Hepatic Stellate Cells and Promotes Liver Fibrogenesis via ERK1/2 Pathway
Regina A. OshinsiD, Zachary GreenbergiD, Yunling Tai, Derrick Zhao, Xuan WangiD, Borna MehradiD, Mei HeiD, Ishan J. PateliD, Laith Khartabil, Huiping ZhouiD, Mark BrantlyiD, Nazli KhodayariiD
Abstract
Liver fibrosis associated with increased mortality is caused by activation of hepatic stellate cells and excessive production and accumulation of extracellular matrix in response to fibrotic insults. It has been shown that in addition to liver inflammation, systemic inflammation also contributes to liver fibrogenesis. A deeper understanding of mechanisms that control liver fibrotic response to intra-and extra-hepatic inflammation is essential to develop novel clinical strategies against this disease. Extracellular vesicles (EV) have been recognized as immune mediators that facilitate activation of hepatic stellate cells. In inflammatory diseases, activated neutrophils release neutrophil elastase (NE) bound to EV, which has been identified as a significant contributor to inflammation by promoting immune cell activation. Here, we aimed to explore the role of inflammation derived plasma EV-associated NE in liver fibrogenesis and its potential mechanisms. We show EV-associated NE induces activation, proliferation and migration of hepatic stellate cells by promoting activation of the ERK1/2 signaling pathway. This effect did not occur through EV without surface NE, and Sivelestat, a NE inhibitor, inhibited activation of the ERK1/2 signaling pathway mediated by EV-associated NE. Moreover, we found plasma EV-associated NE increases deposition of collagen1 and -smooth muscle actin in the liver of a mouse model of liver fibrosis (Mdr2-/-). Notably, this effect does not occur in control mice without preexisting liver disease. These data suggest that EV-associated NE is a pro-fibrogenic factor for hepatic stellate cell activation via the ERK1/2 signaling pathway in pre-existing liver injuries. Inhibition of the plasma EV-associated NE in inflammatory conditions may be a therapeutic target for liver fibrosis in patients with inflammatory diseases.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Extracellular histones stimulate collagen expression and potentially promote liver fibrogenesis via TLR4-MyD88 signalling pathway
Z. wang, z. Cheng, … G. Wang·World Journal of GastroenterologyPeer-reviewed·Dec 21, 2020
- Matrix Stiffness Regulates Liver Sinusoidal Endothelial Cell Function Mimicking Responses in Fatty Liver Disease
V. Natarajan, M. Moeller, … S. Kidambi·bioRxiv·Jan 27, 2020
- Amniotic Fluid Reduces Liver Fibrosis By Attenuating Hepatic Stellate Cell Activation
Charles M. Bowen, Frederick S. Ditmars, … William Samuel Fagg·Stem Cells Translational MedicinePeer-reviewed·May 30, 2025
- 17α-estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice
S. Ali Mondal, R. Sathiaseelan, … M. Stout·bioRxiv·Jun 16, 2022
- The hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche
E. Gonzalez-Sanchez, J. Vaquero, … I. Fabregat·bioRxiv·Nov 3, 2023
- Perivascular matrix densification dysregulates angiogenesis and activates pro-inflammatory endothelial cells
Jingyi Xia, William Y. Wang, … Brendon M. Baker·Advanced SciencePeer-reviewed·Jun 17, 2026